Picture of Baxter International logo

BAX — Baxter International News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Baxter Q1 revenue rises 3%, beats analyst expectations

Overview

Global medtech firm's Q1 revenue rose 3%, beating analyst expectations

Adjusted diluted EPS for Q1 was $0.37, beating analyst expectations

Organic revenue fell 1% due to lower U.S. sales and segment headwinds

Outlook

Baxter sees 2026 reported sales growth from continuing operations flat to 1%

Company expects 2026 organic sales growth from continuing operations to be approximately flat

Baxter forecasts 2026 adjusted EPS from continuing operations of $1.85 to $2.05

Result Drivers

INFUSION THERAPIES & TECHNOLOGIES - Lower infusion pump sales, impacted by shipment and installation hold of Novum IQ LVP and tough prior-year comparison, weighed on segment results

FRONT LINE CARE - Lower sales in Front Line Care due to timing of orders and planned global portfolio exits

HIGHER COSTS - Adjusted EPS decline reflected higher costs related to tariffs and manufacturing, including lower absorption

Company press release: ID:nBw5xRmMLa

Key Details

MetricBeat/MissActualConsensus Estimate
Q1 RevenueBeat$2.70 bln$2.62 bln (12 Analysts)
Q1 Adjusted diluted EPSBeat$0.37$0.31 (13 Analysts)
Q1 Net Income-$15 mln
Analyst Coverage The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 15 "hold" and 1 "sell" or "strong sell" The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy." Wall Street's median 12-month price target for Baxter International Inc is $20.00, about 18.3% above its April 29 closing price of $16.90 The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 8 three months ago For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Baxter International

See all news